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Problem Identification 
• Prostate-specific antigen (PSA) is widely accepted as a valid method to 
detect prostate cancer recurrence; PSA is currently controversial in its 
use in prostate cancer screening (1,2)
• In May 2017, US Preventive Services Task Force proposed a change in 
their previous recommendation for prostate cancer screening from 
“grade D” to “grade C” (3)
• Guidelines for prostate cancer screening from American Cancer Society 
and American Urological Association are not in complete agreement (4,5)
• With no standardization of a prostate cancer screening protocol amongst 
various providers and previous guidelines recommending against 
screening, patients are understandably confused about if they should be 
screened
Public Health Cost
• In the US, prostate cancer is the most common cancer in males 
(excluding skin cancer) resulting in an expected 26,730 deaths in 
2017, making it the 3rd leading cause of cancer death (6)
• Prostate cancer is associated with $12 billion in medical costs (7)
• Since USPSTF previous recommendation of “grade D” was 
published in 2012, there has been significant decrease in PSA 
screening (8)
• Patients who could benefit from treatment are potentially identified too 
late, decreasing favorable outcomes 
Community Perspective
Thanks to the Champlain Valley Prostate Support Group who let me interview them, 
we had a wonderful discussion about their thoughts on screening and their own 
experiences! Here are some of their responses
Phyllis A. Knight (partner of group member): she has a family history of ovarian cancer 
and laments that there is no current screening methods for that, says her relative only 
lived for 3-4 months after finding out. She acknowledges that PSA is not the perfect 
screening tool, but believes that it is better than having nothing and that it’s 
important to take advantage of this tool.
George Schiavone (group member): his PSA hovered in the 1-2 ng/ml and then climbed 
up to 3-4 ng/ml over a 8 year span. However, his provider was hesitant to do anything 
based on his PSA and decided to wait. When he ended up getting his prostate 
biopsied, his Gleason score was 9. He is a firm believer in using PSA for screening and 
adamantly did not agree with the USPSTF’s previous recommendation to not use PSA 
screening at all.
Community Perspective II
Anonymous (group member): he doesn’t believe in using PSA or digital 
rectal exam for screening and endorses that it should be used only when 
symptoms appear because it treadmills into surgery and radiation and 
these treatments can have a lot of side effects.
Anonymous (group member): she has a family history of prostate cancer 
and now has sons. She fully supports having PSA screening done for them 
and urges them to start having those conversations with their providers 
when they turn 40-years-old. She was very happy to learn that the USPSTF 
has recently decided to change their recommendations and believes things 
are heading in the right direction.
Intervention
• Poster motivating patients to start a conversation with their 
provider about prostate cancer screening
• Also educate them about the risk factors associated with prostate cancer to 
ensure that high risk males are more effectively captured in the screening 
process
• Current research is underway at the UVMMC and UVM Cancer 
Center 
• The Modern Approach to Prostate Cancer Screening (MAPS): Headed by Dr. 
Wallace and Dr. Landrey for Primary Care Physicians and Urologists to 
collaborate on a standardized risk-adapted, PSA-based prostate cancer 
screening to identify clinically significant prostate cancer
Results
• Result is a poster promoting awareness among males over 40 to 
have a shared decision-making conversation with their provider 
about appropriateness of prostate cancer screening 
• Posters can be distributed to all UVMMC family practice sites and 
any other sites part of the University of Vermont Health Network
Effectiveness and Limitations
• Patients with certain risk factors are particularly prompted to consider 
screening
• Posters are more visually noticeable; this can be an effective initial step of 
promoting awareness 
• Posters are distributed in high yield locations
• To assess for effectiveness:
• Survey providers to see if they noticed having more conversations with patients about 
prostate cancer screening
• On PRISM, research how many times providers and patients had a talk about screening 
from provider documentation within the past 3 months
• Limitations include: 
• dissemination not being widespread enough to capture as many eligible males as possible
• Some may not take the time to read the poster
Recommendations for Future Interventions
• To reach a more widespread audience, further dissemination of 
importance of prostate cancer screening by:
• writing an article for the Hinesburg Record and UVMMC blog
• Presenting at the Men’s Health and Cancer Conference
• Update information if new guideline recommendations or 
knowledge regarding screening practices change 
• To assess if more shared decision-making conversations about 
screening resulted in diagnosis of clinically significant prostate 
cancer
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